Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists

Omid Zahedi Niaki, Milan J. Anadkat, Steven T. Chen, Lindy P. Fox, Joanna Harp, Robert G. Micheletti, Vinod E. Nambudiri, Helena B. Pasieka, Michi M. Shinohara, Misha Rosenbach, Joseph F. Merola

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in coronavirus disease 2019 (COVID-19) are scarce. This article reviews and offers guidance based on currently available safety data and the most recent COVID-19 outcome data in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasizes a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic.

Original languageEnglish
Pages (from-to)1150-1159
Number of pages10
JournalJournal of the American Academy of Dermatology
Volume83
Issue number4
DOIs
StatePublished - Oct 2020

Keywords

  • COVID-19
  • SARS-CoV-2
  • autoimmune disease
  • dermatology-rheumatology
  • immunosuppression
  • immunosuppressive therapy
  • medical dermatology

Fingerprint

Dive into the research topics of 'Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists'. Together they form a unique fingerprint.

Cite this